MX2022002693A - Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion. - Google Patents

Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion.

Info

Publication number
MX2022002693A
MX2022002693A MX2022002693A MX2022002693A MX2022002693A MX 2022002693 A MX2022002693 A MX 2022002693A MX 2022002693 A MX2022002693 A MX 2022002693A MX 2022002693 A MX2022002693 A MX 2022002693A MX 2022002693 A MX2022002693 A MX 2022002693A
Authority
MX
Mexico
Prior art keywords
polysaccharide
typhi
methods
salmonella
preparation
Prior art date
Application number
MX2022002693A
Other languages
English (en)
Inventor
Sambhaji Shankar Pisal
Rajeev Mhalasakant Dhere
Dattatreya Sarma Annamraju
Nikhil Dattatray Avalaskar
Yogesh Tukaram Hundekari
Anil Pirajirao Taklikar
Sunil Kumar Goel
Chandrashekhar Dwarkanath Kamat
Vishal Bharat Chavan
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of MX2022002693A publication Critical patent/MX2022002693A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a nuevas composiciones inmunogénicas de vacuna conjugadas de polisacárido-proteína monovalentes y multivalentes de polisacárido-proteína que comprenden un polisacárido seleccionado de cepas de Salmonella serovar S. typhi; S. paratyphi A; S. typhimurium y S. enteritidis y métodos alternativos mejorados de fermentación de polisacáridos, purificación de polisacáridos, conjugación de polisacáridos-proteína y formulación estable. La presente divulgación se refiere además a métodos para inducir una respuesta inmune en sujetos contra Salmonella typhi y enfermedades no relacionadas con typhi o para reducir o prevenir Salmonella typhi y enfermedades no relacionadas con typhi en sujetos que usen las composiciones descritas en este documento. La vacuna provoca anticuerpos bactericidas y es útil para la prevención de gastroenteritis, fiebre entérica y tifoidea.
MX2022002693A 2019-09-03 2020-09-02 Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion. MX2022002693A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Publications (1)

Publication Number Publication Date
MX2022002693A true MX2022002693A (es) 2022-07-12

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002693A MX2022002693A (es) 2019-09-03 2020-09-02 Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion.

Country Status (20)

Country Link
US (1) US20230149524A1 (es)
EP (2) EP4249061A3 (es)
JP (1) JP2022546763A (es)
KR (1) KR20220087437A (es)
CN (1) CN114728053A (es)
AR (1) AR119884A1 (es)
AU (1) AU2020343943A1 (es)
BR (1) BR112022003892A2 (es)
CA (1) CA3149972A1 (es)
CO (1) CO2022003789A2 (es)
CR (1) CR20220132A (es)
EC (1) ECSP22031077A (es)
GB (1) GB2603362A (es)
IL (1) IL291006A (es)
JO (1) JOP20200214A1 (es)
MA (1) MA56283A1 (es)
MX (1) MX2022002693A (es)
PE (1) PE20221442A1 (es)
WO (1) WO2021044436A2 (es)
ZA (1) ZA202203368B (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
AU771330B2 (en) 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP1896062B1 (en) 2005-06-27 2010-03-31 GlaxoSmithKline Biologicals S.A. Immunogenic composition
TW201516149A (zh) 2006-09-13 2015-05-01 Abbvie Inc 細胞培養改良
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
BR122022002084B1 (pt) * 2009-12-17 2022-08-16 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
SI2809349T1 (sl) 2012-01-30 2019-03-29 Serum Institute Of India Private Limited Imunogeni sestavek
CN102935226B (zh) * 2012-11-16 2014-01-22 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
KR102447303B1 (ko) * 2013-08-24 2022-09-23 브하라트 바이오테크 인터내셔날 리미티드 박테리아성 백신 및 그의 제조방법
EA039487B1 (ru) * 2015-07-04 2022-02-01 Бхарат Байотек Интернэшнл Лимитед Комбинированные полисахаридные вакцинные композиции и способ получения бактериальных капсульных полисахаридов
CA3032901A1 (en) 2016-08-26 2018-03-01 Serum Institute Of India Private Limited Multivalent vaccine composition
EP3619241A1 (en) * 2017-05-05 2020-03-11 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
EP3655024A1 (en) 2017-07-18 2020-05-27 Serum Institute of India Private Limited An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Also Published As

Publication number Publication date
BR112022003892A2 (pt) 2022-05-24
EP4249061A2 (en) 2023-09-27
US20230149524A1 (en) 2023-05-18
ECSP22031077A (es) 2022-05-31
AR119884A1 (es) 2022-01-19
MA56283A1 (fr) 2023-01-31
PE20221442A1 (es) 2022-09-21
JP2022546763A (ja) 2022-11-08
CR20220132A (es) 2022-05-06
JOP20200214A1 (ar) 2021-03-03
WO2021044436A3 (en) 2021-05-27
EP4249061A3 (en) 2023-11-15
KR20220087437A (ko) 2022-06-24
GB202204276D0 (en) 2022-05-11
WO2021044436A2 (en) 2021-03-11
AU2020343943A1 (en) 2022-03-24
IL291006A (en) 2022-05-01
GB2603362A (en) 2022-08-03
EP4025246A2 (en) 2022-07-13
CN114728053A (zh) 2022-07-08
CO2022003789A2 (es) 2022-04-19
CA3149972A1 (en) 2021-03-11
ZA202203368B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
MX2020005779A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
Plotkin et al. A new typhoid vaccine composed of the Vi capsular polysaccharide
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CR20210333A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
JP2004512269A5 (es)
TW200722101A (en) Novel composition
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
RU2012138368A (ru) 15-валентная вакцинная композиция на основе конъюгата пневмококкового полисахарида с белком
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
JP2020114838A (ja) 百日咳菌免疫原性ワクチン組成物
Gaines et al. STUDIES ON INFECTION AND IMMUNITY IN EXPERIMENTAL TYPHOID FEVER: III. EFFECT OF PROPHYLACTIC IMMUNIZATION
MX2022002693A (es) Composiciones inmunogenicas contra enfermedades entericas y metodos para su preparacion.
WO2010083477A3 (en) Broad spectrum vaccine against non-typhoidal salmonella
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
Amini et al. Evaluation of the immunogenicity of diphtheria toxoid conjugated to salmonella typhimurium-derived OPS in a mouse model: a potential vaccine candidate against salmonellosis
Donachie Vaccine development against Pasteurella haemolytica infections in sheep
Beuvery Immunisation against bacterial meningitis
Holmgren et al. Vaccines against bacterial enteric infections
Underdown et al. Parenteral immunization and protection from mucosal infection
MX2015017677A (es) Vacuna multivalente que contiene porinas de s. typhi y s. typhimurium contra fiebre tifoidea, paratifoidea y salmonelosis no tifoideas.
Rivera-Patron et al. Quillaja brasiliensis leaf saponins and their nanoparticles are strong inducers of early immune responses
US20210401960A1 (en) Multivalent glycoconjugates immunogenic compositions
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
Szu et al. Escherichia coli O157
LEVINE et al. Immunology of Enteric